Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zylox-Tonbridge Medical Technology CoHKSE:02190 +3.05%82 Shareholder Yield % is 3.36% as of Dec. 2025, which is 500% above its 10-year median of 0.56. GuruFocus rates HKSE:02190 with a GF Score™ of 82/100 and a GF Value™ of HK$35.80 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Zylox-Tonbridge Medical Technology Co ranks better than 77.45% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Zylox-Tonbridge Medical Technology Co's Shareholder Yield % was 3.36%.
Zylox-Tonbridge Medical Technology Co (HKSE:02190) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Zylox-Tonbridge Medical Technology Co Shareholder Yield % Related Terms
Zylox-Tonbridge Medical Technology Co Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co Shareholder Yield % Chart
HKSE:02190 vs ABT, SYK, MDT: Shareholder Yield % Comparison
For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zylox-Tonbridge Medical Technology Co Shareholder Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Zylox-Tonbridge Medical Technology Co (HKSE:02190) has a Shareholder Yield % of 3.36% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. This is 500% above median its historical median of 0.56. According to the industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #184 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 22.5%.
Is Zylox-Tonbridge Medical Technology Co's Shareholder Yield % too high?
Zylox-Tonbridge Medical Technology Co's current Shareholder Yield % of 3.36% is 500% above median its 10-year median of 0.56. The Medical Devices & Instruments industry median Shareholder Yield % is 0.20. Zylox-Tonbridge Medical Technology Co's value of 3.36% is 1623.1% above this industry median. Based on the distribution chart, Zylox-Tonbridge Medical Technology Co ranks #184 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's Shareholder Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #184 out of 816 companies for Shareholder Yield %. This places Zylox-Tonbridge Medical Technology Co in the top 23% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.20. Zylox-Tonbridge Medical Technology Co's value of 3.36% is 1623.1% above this benchmark. While the company's 10-year median is 0.56 vs. the industry median of 0.20, Zylox-Tonbridge Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Devices & Instruments company?
The median Shareholder Yield % among Medical Devices & Instruments companies is 0.20, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zylox-Tonbridge Medical Technology Co's current Shareholder Yield % of 3.36% is 1623.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median Shareholder Yield % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zylox-Tonbridge Medical Technology Co's current Shareholder Yield % is 3.36%, which is 500% above median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (HKSE:02190) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$35.80, compared to a current price of HK$19.95 — trading 44.3% below its estimated fair value. The current Shareholder Yield % is 3.36%, which is 500% above median its 10-year median of 0.56 and 1623.1% above the Medical Devices & Instruments industry median of 0.20. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (HKSE:02190), the current Shareholder Yield % is 3.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zylox-Tonbridge Medical Technology Co (HKSE:02190) Overvalued in 2026?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued.
The current stock price of HK$19.95 is trading 44.3% below its estimated GF Value™ of HK$35.80.
GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02190:
Shareholder Yield %: 3.36% (500% above median its 10-year median of 0.56)
GF Value™: HK$35.80 vs. price of HK$19.95 (44.3% below fair value)
Industry Position: 1623.1% above the Medical Devices & Instruments median (#184 of 816)
No single metric tells the full story. See the HKSE:02190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
82GF Score
Get the complete analysis for HKSE:02190
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02190 has been successfully added to your 
